Limits...
Clinical efficacy and safety of hypernormal shortened door to needle time (DNT) plus individualized low-dose alteplase therapy in treating acute ischemic stroke

View Article: PubMed Central - PubMed

ABSTRACT

Objective:: This study aims to observe the clinical efficacies of hyper-early low-dose alteplase thrombolysis in treating acute ischemic stroke (AIS).

Methods:: Two hundred twenty AIS patients were randomly divided into group A (90 cases), group B (90 cases), and group C (40 cases). The National Institutes of Health Stroke Scale (NIHSS) scores, mRS score-evaluated prognosis, intracranial hemorrhage, and mortality of the three groups were observed before and after the treatment.

Results:: The NIHSS scores of the three groups were significantly reduced after the treatment (P<0.05), among which the NIHSS score of group A was the lowest (P<0.05); and the difference between group B and C was not significant (P>0.05). The incidence of such complications as cerebral hemorrhage in the three groups was low, and there was no significant difference among the groups (P>0.05). The modified Rankin Scale (mRS)scores of the three groups showed that group A had much better prognosis than group B and C, while the difference between group B and group C was not significant.

Conclusions:: The hyper-early low-dose alteplase thrombolysis was safe and effective in Acute ischemic stroke (AIS).

No MeSH data available.


Related in: MedlinePlus

NIHSS scores of the three groups before and after the treatment; *compared with those before the treatment, P<0.05; &compared with group B after the treatment, P<0.05; #compared with group C after the treatment, P<0.05.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC5017082&req=5

Figure 1: NIHSS scores of the three groups before and after the treatment; *compared with those before the treatment, P<0.05; &compared with group B after the treatment, P<0.05; #compared with group C after the treatment, P<0.05.

Mentions: The comparisons of the NIHSS scores of the three groups before the treatment and at H1, H24, D7, D30, and D90 after the treatment revealed that the neurological functions of the three groups were all effectively improved (Fig.1). Compared with the NIHSS score before the treatment, those at H1, H24, D7, D30, and D90 after the treatment were all significantly reduced, and the differences were significant (P<0.05); and the NIHSS scores exhibited the significantly decreasing trend with the prolonged treatment time. Compared with group B and C, the NIHSS scores of group A at H1, H24, D7, D30, and D90 after the treatment were lower (P<0.05); while the differences between group B and C were not significant (P>0.05), indicating that the efficacies of the hypernormal shortened DNT thrombolytic treatment were significantly better than the conventional thrombolytic programs, and the thrombolytic effects of low-dose alteplase showed no difference with those required by the conventional thrombolytic programs.


Clinical efficacy and safety of hypernormal shortened door to needle time (DNT) plus individualized low-dose alteplase therapy in treating acute ischemic stroke
NIHSS scores of the three groups before and after the treatment; *compared with those before the treatment, P<0.05; &compared with group B after the treatment, P<0.05; #compared with group C after the treatment, P<0.05.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC5017082&req=5

Figure 1: NIHSS scores of the three groups before and after the treatment; *compared with those before the treatment, P<0.05; &compared with group B after the treatment, P<0.05; #compared with group C after the treatment, P<0.05.
Mentions: The comparisons of the NIHSS scores of the three groups before the treatment and at H1, H24, D7, D30, and D90 after the treatment revealed that the neurological functions of the three groups were all effectively improved (Fig.1). Compared with the NIHSS score before the treatment, those at H1, H24, D7, D30, and D90 after the treatment were all significantly reduced, and the differences were significant (P<0.05); and the NIHSS scores exhibited the significantly decreasing trend with the prolonged treatment time. Compared with group B and C, the NIHSS scores of group A at H1, H24, D7, D30, and D90 after the treatment were lower (P<0.05); while the differences between group B and C were not significant (P>0.05), indicating that the efficacies of the hypernormal shortened DNT thrombolytic treatment were significantly better than the conventional thrombolytic programs, and the thrombolytic effects of low-dose alteplase showed no difference with those required by the conventional thrombolytic programs.

View Article: PubMed Central - PubMed

ABSTRACT

Objective:: This study aims to observe the clinical efficacies of hyper-early low-dose alteplase thrombolysis in treating acute ischemic stroke (AIS).

Methods:: Two hundred twenty AIS patients were randomly divided into group A (90 cases), group B (90 cases), and group C (40 cases). The National Institutes of Health Stroke Scale (NIHSS) scores, mRS score-evaluated prognosis, intracranial hemorrhage, and mortality of the three groups were observed before and after the treatment.

Results:: The NIHSS scores of the three groups were significantly reduced after the treatment (P&lt;0.05), among which the NIHSS score of group A was the lowest (P&lt;0.05); and the difference between group B and C was not significant (P&gt;0.05). The incidence of such complications as cerebral hemorrhage in the three groups was low, and there was no significant difference among the groups (P&gt;0.05). The modified Rankin Scale (mRS)scores of the three groups showed that group A had much better prognosis than group B and C, while the difference between group B and group C was not significant.

Conclusions:: The hyper-early low-dose alteplase thrombolysis was safe and effective in Acute ischemic stroke (AIS).

No MeSH data available.


Related in: MedlinePlus